Company profile
OS Therapies Incorporated
AMEX: OSTX · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 15DQ —GM —SS 27
v0.1 · 35/100 weight · pillars only
↑ market scale, Altman-Z · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$28.8M
Employees
5
as of 2026-08-18
Market cap
$65.5M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$28.8M-$28.8M2025
Operating income-$28.7M-$28.7M2025
Total assets$6.8M$6.8M2025
Liabilities$11.9M$11.9M2025
Equity-$6.1M-$6.1M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is OS Therapies Incorporated’s financial profile?
OS Therapies Incorporated earned -$28.8M in FY2025 net income.
Peers · Healthcare
Cingulate Inc.——Instinct Bio Technical Co. Holdings Inc.——PMV Pharmaceuticals, Inc.——Citius Oncology, Inc.——Atlantic International Corp——Boundless Bio, Inc.——Key facts
CEOPaul A. Romness
SectorHealthcare
IndustryBiotechnology
HeadquartersGrasonville, MD
ExchangeAMEX: OSTX
Employees5
IPO date2024-08-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.